{"id":"https://openalex.org/W2029974635","doi":"https://doi.org/10.1248/bpb.32.637","title":"Relationship between Serum Aprindine Concentration and Neurologic Side Effects in Japanese","display_name":"Relationship between Serum Aprindine Concentration and Neurologic Side Effects in Japanese","alternate_titles":[],"publication_year":2009,"publication_date":"2009-04-01","ids":{"openalex":"https://openalex.org/W2029974635","doi":"https://doi.org/10.1248/bpb.32.637","mag":"2029974635","pmid":"https://pubmed.ncbi.nlm.nih.gov/19336897"},"language":"en","primary_location":{"id":"doi:10.1248/bpb.32.637","doi":"https://doi.org/10.1248/bpb.32.637","is_oa":true,"landing_page_url":"https://doi.org/10.1248/bpb.32.637","pdf_url":"https://www.jstage.jst.go.jp/article/bpb/32/4/32_4_637/_pdf","source":{"id":"https://openalex.org/S165235614","display_name":"Biological and Pharmaceutical Bulletin","issn_l":"0918-6158","issn":["0918-6158","1347-5215"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310313382","host_organization_name":"Pharmaceutical Society of Japan","host_organization_lineage":["https://openalex.org/P4310313382"],"host_organization_lineage_names":["Pharmaceutical Society of Japan"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biological and Pharmaceutical Bulletin","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2029974635"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://www.jstage.jst.go.jp/article/bpb/32/4/32_4_637/_pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5010607660","display_name":"Yoshimasa Tsuchishita","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405284398","display_name":"Maizuru Kyosai Hospital","ror":"https://ror.org/03fwvgr32","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4405257210","https://openalex.org/I4405284398"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Yoshimasa Tsuchishita","raw_affiliation_strings":["Department of Pharmacy, Maizuru Kyosai Hospital, Federation of National Public Services and Affiliated Mutual Associations"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, Maizuru Kyosai Hospital, Federation of National Public Services and Affiliated Mutual Associations","institution_ids":["https://openalex.org/I4405284398"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111960378","display_name":"Kyoko Fukumoto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114838220","display_name":"Niigata University of Pharmacy and Medical and Life Sciences","ror":"https://ror.org/00dnbtf70","country_code":"JP","type":"education","lineage":["https://openalex.org/I114838220"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Kyoko Fukumoto","raw_affiliation_strings":["Department of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences","institution_ids":["https://openalex.org/I114838220"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032608231","display_name":"Masaaki Kusumoto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405284398","display_name":"Maizuru Kyosai Hospital","ror":"https://ror.org/03fwvgr32","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4405257210","https://openalex.org/I4405284398"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Masaaki Kusumoto","raw_affiliation_strings":["Department of Pharmacy, Maizuru Kyosai Hospital, Federation of National Public Services and Affiliated Mutual Associations"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, Maizuru Kyosai Hospital, Federation of National Public Services and Affiliated Mutual Associations","institution_ids":["https://openalex.org/I4405284398"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101471743","display_name":"Kazuyuki Ueno","orcid":"https://orcid.org/0000-0001-8014-8109","observed_orcids":["https://orcid.org/0000-0001-8014-8109"]},"institutions":[{"id":"https://openalex.org/I114838220","display_name":"Niigata University of Pharmacy and Medical and Life Sciences","ror":"https://ror.org/00dnbtf70","country_code":"JP","type":"education","lineage":["https://openalex.org/I114838220"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Kazuyuki Ueno","raw_affiliation_strings":["Department of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences","institution_ids":["https://openalex.org/I114838220"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.1904,"has_fulltext":true,"cited_by_count":4,"citation_normalized_percentile":{"value":0.49540244,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":93},"biblio":{"volume":"32","issue":"4","first_page":"637","last_page":"639"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.7089999914169312,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.7089999914169312,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11036","display_name":"Antibiotics Pharmacokinetics and Efficacy","score":0.059300001710653305,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11064","display_name":"Antiplatelet Therapy and Cardiovascular Diseases","score":0.032999999821186066,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/aprindine","display_name":"aprindine","score":0.9940000176429749},{"id":"https://openalex.org/keywords/serum-drug-levels","display_name":"serum drug concentration","score":0.7860000133514404},{"id":"https://openalex.org/keywords/neurologic-side-effects","display_name":"neurologic side effects","score":0.9229999780654907},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.47999998927116394},{"id":"https://openalex.org/keywords/therapeutic-drug-monitoring","display_name":"therapeutic drug monitoring","score":0.628000020980835},{"id":"https://openalex.org/keywords/intention-tremor","display_name":"intention tremor","score":0.7059999704360962},{"id":"https://openalex.org/keywords/dizziness","display_name":"dizziness","score":0.9760000109672546},{"id":"https://openalex.org/keywords/japanese-patients","display_name":"Japanese patients","score":0.7049999833106995},{"id":"https://openalex.org/keywords/antipsychotic-side-effects","display_name":"antipsychotic adverse effects","score":0.5839999914169312}],"concepts":[{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.42828431725502014},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4219292998313904},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.35149890184402466},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.32191094756126404}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000367","descriptor_name":"Age Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000889","descriptor_name":"Anti-Arrhythmia Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000889","descriptor_name":"Anti-Arrhythmia Agents","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D001073","descriptor_name":"Aprindine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D001073","descriptor_name":"Aprindine","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007564","descriptor_name":"Japan","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020258","descriptor_name":"Neurotoxicity Syndromes","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D020258","descriptor_name":"Neurotoxicity Syndromes","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D020258","descriptor_name":"Neurotoxicity Syndromes","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1248/bpb.32.637","doi":"https://doi.org/10.1248/bpb.32.637","is_oa":true,"landing_page_url":"https://doi.org/10.1248/bpb.32.637","pdf_url":"https://www.jstage.jst.go.jp/article/bpb/32/4/32_4_637/_pdf","source":{"id":"https://openalex.org/S165235614","display_name":"Biological and Pharmaceutical Bulletin","issn_l":"0918-6158","issn":["0918-6158","1347-5215"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310313382","host_organization_name":"Pharmaceutical Society of Japan","host_organization_lineage":["https://openalex.org/P4310313382"],"host_organization_lineage_names":["Pharmaceutical Society of Japan"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biological and Pharmaceutical Bulletin","raw_type":"journal-article"},{"id":"pmid:19336897","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19336897","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biological & pharmaceutical bulletin","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1248/bpb.32.637","doi":"https://doi.org/10.1248/bpb.32.637","is_oa":true,"landing_page_url":"https://doi.org/10.1248/bpb.32.637","pdf_url":"https://www.jstage.jst.go.jp/article/bpb/32/4/32_4_637/_pdf","source":{"id":"https://openalex.org/S165235614","display_name":"Biological and Pharmaceutical Bulletin","issn_l":"0918-6158","issn":["0918-6158","1347-5215"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310313382","host_organization_name":"Pharmaceutical Society of Japan","host_organization_lineage":["https://openalex.org/P4310313382"],"host_organization_lineage_names":["Pharmaceutical Society of Japan"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biological and Pharmaceutical Bulletin","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2029974635.pdf","grobid_xml":"https://content.openalex.org/works/W2029974635.grobid-xml"},"referenced_works_count":12,"referenced_works":["https://openalex.org/W1966222553","https://openalex.org/W1979392961","https://openalex.org/W1981036449","https://openalex.org/W1984724388","https://openalex.org/W2028834356","https://openalex.org/W2032460077","https://openalex.org/W2038635263","https://openalex.org/W2053893189","https://openalex.org/W2060994846","https://openalex.org/W2132708590","https://openalex.org/W2339523230","https://openalex.org/W2419676072"],"related_works":["https://openalex.org/W2054772636","https://openalex.org/W2038635263","https://openalex.org/W2419247218","https://openalex.org/W2464588181","https://openalex.org/W2091295517","https://openalex.org/W2033871835","https://openalex.org/W2429137632","https://openalex.org/W4244729137","https://openalex.org/W2517876365","https://openalex.org/W2402587167"],"abstract_inverted_index":{"The":[0],"aim":[1],"of":[2,24,29,65,75,101,137],"this":[3],"study":[4],"was":[5,50,82],"to":[6,69,161],"evaluate":[7],"the":[8,11,21,27,70,96,102,115,144],"relationship":[9],"between":[10,52,61],"neurologic":[12,30,89,105,163],"side":[13,31,90,106,116,164],"effects":[14,32,91,107,117],"associated":[15,92,118],"with":[16,93,119],"serum":[17,55,66,148],"aprindine":[18,25,38,56,67,76,80,109,120,138,149],"concentrations":[19,39,110],"and":[20,54,60,63],"safety":[22],"range":[23],"for":[26],"prevention":[28],"in":[33,129,143,158],"142":[34],"Japanese":[35,159],"inpatients.":[36],"Serum":[37],"were":[40,111,127],"determined":[41],"by":[42],"high-performance":[43],"liquid":[44],"chromatography.":[45],"A":[46],"poor":[47],"positive":[48],"correlation":[49],"observed":[51,128],"dose":[53,71],"concentration":[57,68,81,150],"(r(2)=0.0419,":[58],"p=0.0114),":[59],"age":[62],"ratio":[64],"per":[72],"body":[73],"weight":[74],"(r(2)=0.0159,":[77],"p=0.121).":[78],"When":[79],"<1":[83],"microg/ml,":[84],"almost":[85],"no":[86],"patients":[87,103,160],"showed":[88,104],"aprindine.":[94],"On":[95],"other":[97],"hand,":[98],"about":[99],"50%":[100],"when":[108],">1":[112],"microg/ml.":[113],"Here,":[114],"such":[121],"as":[122],"dizziness":[123],"or":[124,140],"intention":[125],"tremors":[126],"15":[130],"patients,":[131],"which":[132],"later":[133],"disappeared":[134],"after":[135],"discontinuance":[136],"therapy":[139],"a":[141],"decrease":[142],"dose.":[145],"In":[146],"conclusion,":[147],"should":[151],"be":[152],"maintained":[153],"under":[154],"approximately":[155],"1":[156],"microg/ml":[157],"prevent":[162],"effects.":[165]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2029974635","counts_by_year":[{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2017,"cited_by_count":1}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
